Physician profile
Samuel Pan
NPI 1871728741
$2,122.44
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $621 · 2020: $229 · 2021: $289 · 2022: $746 · 2023: $215 · 2024: $21.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $237.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $562.94 | 2019-2023 | |
| Janssen Products, LP | $409.02 | 2019-2022 | |
| Janssen Biotech, INC. | $351.79 | 2019-2022 | |
| Viiv Healthcare Company | $321.54 | 2021-2023 | Dovato, Rukobia, Apretude |
| Biomerieux INC | $180.89 | 2022 | |
| Merck Sharp & Dohme LLC | $97.83 | 2019-2020 | |
| Abbvie INC. | $72.22 | 2019-2023 | |
| Insmed, INC. | $37.77 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Sanofi Pasteur INC. | $23.29 | 2019 | |
| Melinta Therapeutics, LLC | $21.96 | 2024 | Rezzayo, Vabomere, Kimyrsa |
| Theratechnologies INC. | $14.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Pan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.